Upperton Is Successful Recipient of FP7 European Research Grant
Nottingham, 1 June 2012 -Upperton Limited today announced that it has been successful in securing a Framework Programme 7 Grant to support its role in the "Nanodetector" project.. The project will run from June 2012-November 2015.
The aim of the project is the development of a new technology for detection and analysis of single nanoparticles in complex environments leading to the development of a laboratory prototype based on this technology. The detection method utilised by the new machine is based on an experimental nano-detection phenomenon discovered recently by one of the project partners.
The aim of the project is to develop a "nanoparticle detector", which can both detect and analyse single nanoparticles in complex natural environments. The technology is based on an experimental nano-detection phenomenon discovered recently by one of the project partners. This detection method will be used in an innovative "nanoparticle detector" machine.
Uppertons' role in the project will be to assist in the development of novel detection methods for biological nanoparticles produced using its platform rp-nanoTM technology. These novel nanoparticles are currently being used to enhance the delivery of drugs, peptides and proteins in a wide range of medical applications including oncology and next-generation vaccines.
Dr Richard Johnson, founder and CEO of Upperton Limited, commented "Upperton is delighted to be included in a European consortium that includes such a wide range of prestigious organisations. We believe that our rP-nanoTM delivery technology has broad utility across the pharmaceutical and biotechnology industry which makes it an ideal test-candidate for this exciting new detection system"
The 9 consortium members are made up of Leibniz-
Note to Editor:
Upperton is a Research and Development company that offers a broad range of novel formulation and drug delivery technologies for the pharmaceutical and biotechnology industry.
Tel: +44 (0)115 955 3387
Dr Richard Johnson, CEO Email: